AVAH
Aveanna Healthcare Holdings Inc.8.84
-0.05-0.56%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.85BP/E (TTM)
23.89Basic EPS (TTM)
0.37Dividend Yield
0%Recent Filings
8-K
Director resigns immediately
Aveanna Healthcare's Class I director Robert M. Williams, Jr. resigned from the Board effective February 27, 2026, with no disagreements on operations, policies, or practices. He previously sat on the Nominating and Corporate Governance, Compensation, and Clinical Quality and Compliance Committees. Board loses key oversight voice.
8-K
New exec employment agreements
Aveanna inked new employment deals February 17, 2026, for CEO Jeff Shaner ($750K base, 100% target bonus), CFO Matthew Buckhalter ($500K base, 75% bonus), and CLO Jerry Perchik ($450K base, 75% bonus), replacing priors. Severance jumps to 2.5x for Shaner in change-of-control scenarios, with full equity vesting. Locks in leadership continuity. Restrictive covenants bind tight.
8-K
Raised 2025 guidance, 2026 debut
Aveanna raised FY2025 guidance to $2.425-$2.445B revenue and $318-$322M Adjusted EBITDA, up from prior thresholds, while launching FY2026 outlook at $2.54-$2.56B revenue and matching $318-$322M Adjusted EBITDA. Figures reconcile fully from projected net income of $181-$220M. Results preliminary, pending audit.
8-K
Board change, stock rules amended
Aveanna Healthcare amended its stockholders agreement on November 13, 2025, restricting executive stock transfers to Compensation Committee approval and compliance with ownership guidelines, while freeing certain other stockholders. Board swap: Christopher Gordon resigned as Class II director; Bain's Sam Weil, 35, filled the seat immediately, joining the Compensation Committee as independent. Governance tightened yet sponsor influence holds.
8-K
Q3 revenue jumps 22%
Aveanna released its November 2025 investor presentation via 8-K, showcasing Q3 revenue up 22.2% to $621.9M and Adjusted EBITDA surging 67.5% to $80.1M versus Q3 2024. PDS drove 25.6% growth on 12.9% volume gains; YTD free cash flow hit positive $86.2M. Targets 7-10% long-term growth via value-based payor deals, yet risks like reimbursement shifts loom.
IPO
Website
Employees
Sector
Industry
ACHC
Acadia Healthcare Company, Inc.
14.43+0.21
ADUS
Addus HomeCare Corporation
113.49-1.65
AHCO
AdaptHealth Corp.
10.35+0.08
ASTH
Astrana Health Inc.
22.31+0.01
AVNS
Avanos Medical, Inc.
11.62-0.24
EHAB
Enhabit, Inc.
9.61-0.08
INNV
InnovAge Holding Corp.
5.55-0.27
MD
Pediatrix Medical Group, Inc.
22.32-0.37
PNTG
The Pennant Group, Inc.
29.73+0.00
VMD
Viemed Healthcare, Inc.
7.26-0.11